Difference between revisions of "Pixantrone (Pixuvri)"
Jump to navigation
Jump to search
m |
m |
||
Line 13: | Line 13: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
+ | [[Category:Intravenous chemotherapy]] | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
− | [[Category: | + | [[Category:Diffuse large B-cell lymphoma medications]] |
[[Category:Drugs EMA approved in 2013]] | [[Category:Drugs EMA approved in 2013]] |
Revision as of 01:29, 20 July 2017
Although this drug is EMA approved as of 5/31/2013, it is not yet FDA approved.
Mechanism of action
From the NCI Drug Dictionary: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Route: IV
Diseases for which it is used
Also known as
BBR 2778, Pixantrone dimaleate